MX2020001342A - Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. - Google Patents
Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.Info
- Publication number
- MX2020001342A MX2020001342A MX2020001342A MX2020001342A MX2020001342A MX 2020001342 A MX2020001342 A MX 2020001342A MX 2020001342 A MX2020001342 A MX 2020001342A MX 2020001342 A MX2020001342 A MX 2020001342A MX 2020001342 A MX2020001342 A MX 2020001342A
- Authority
- MX
- Mexico
- Prior art keywords
- gaboxadol
- pharmaceutically acceptable
- acceptable salt
- metabolic disease
- level
- Prior art date
Links
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 title abstract 4
- 229950004346 gaboxadol Drugs 0.000 title abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 title 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 3
- 208000030159 metabolic disease Diseases 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007410 oral glucose tolerance test Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541260P | 2017-08-04 | 2017-08-04 | |
| PCT/US2018/044973 WO2019028234A1 (en) | 2017-08-04 | 2018-08-02 | USE OF GABOXADOL IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020001342A true MX2020001342A (es) | 2020-08-31 |
Family
ID=65230918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020001342A MX2020001342A (es) | 2017-08-04 | 2018-08-02 | Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US10813918B2 (OSRAM) |
| EP (1) | EP3648762A4 (OSRAM) |
| JP (1) | JP2020529440A (OSRAM) |
| KR (1) | KR20200047557A (OSRAM) |
| CN (1) | CN111201022A (OSRAM) |
| AU (1) | AU2018309049A1 (OSRAM) |
| CA (1) | CA3071939A1 (OSRAM) |
| IL (1) | IL272414A (OSRAM) |
| MX (1) | MX2020001342A (OSRAM) |
| WO (1) | WO2019028234A1 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20200047557A (ko) | 2017-08-04 | 2020-05-07 | 오비드 테라퓨틱스 인크. | 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용 |
| IL322968A (en) | 2017-10-12 | 2025-10-01 | Novo Nordisk As | Semaglutide in medical treatment |
| CN113395962A (zh) | 2018-11-21 | 2021-09-14 | Certego治疗公司 | 加波沙朵用于降低自杀风险和快速缓解抑郁症 |
| AU2020405060A1 (en) | 2019-12-18 | 2022-06-09 | Ovid Therapeutics Inc. | Gaboxadol for therapeutic treatment of 1p36 deletion syndrome |
| AU2021275863A1 (en) | 2020-05-20 | 2023-02-02 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| AU2023255685A1 (en) * | 2022-04-20 | 2024-12-05 | Aclipse Two Inc. | Treatment of gastrointestinal diseases |
| WO2025049710A1 (en) * | 2023-08-29 | 2025-03-06 | Aclipse Two Inc. | Pharmaceutical composition for use in the disease treatments |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| GB0402118D0 (en) | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| MXPA06011325A (es) | 2004-04-02 | 2006-12-15 | Lundbeck & Co As H | Tratamiento de la funcion respiratoria alterada con gaboxadol. |
| ZA200607427B (en) * | 2004-04-02 | 2009-02-25 | Lundbeck & Co As H | Treatment of impaired respiratory function with gaboxadol |
| EP1863808A1 (en) * | 2005-03-18 | 2007-12-12 | Transform Pharmaceuticals, Inc. | Gaboxadol forms, compositions thereof, and related methods |
| DE102005020882A1 (de) * | 2005-05-04 | 2006-11-09 | Dömling, Alexander, Dr. | Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten |
| US20110046090A1 (en) | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| US7635710B2 (en) | 2006-02-15 | 2009-12-22 | Neurim Pharmaceuticals (1991) Ltd. | Pyrone-indole derivatives and process for their preparation |
| WO2008066750A1 (en) | 2006-11-22 | 2008-06-05 | Seaside Therapeutics, Llc | Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism |
| TW200920358A (en) | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| WO2009117367A1 (en) * | 2008-03-18 | 2009-09-24 | Bristol-Myers Squibb Company | Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof |
| WO2012050907A2 (en) | 2010-09-28 | 2012-04-19 | The Regents Of The University Of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
| WO2013024047A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| PL3372229T3 (pl) | 2014-06-06 | 2021-10-04 | Ovid Therapeutics, Inc. | Sposoby zwiększenia hamowania tonicznego i leczenia zespołu angelmana |
| EP3154979B1 (en) | 2014-06-12 | 2018-03-07 | Pfizer Limited | Imidazopyridazine derivatives as modulators of the gabaa receptor activity. |
| WO2016102657A1 (en) * | 2014-12-23 | 2016-06-30 | Novo Nordisk A/S | Alpha-cell re-generation combined with conversion to beta cells |
| US9682069B2 (en) * | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| MX391708B (es) | 2015-07-17 | 2025-03-21 | Ovid Therapeutics Inc | Metodos para tratar trastornos del desarrollo con gaboxadol. |
| US20170348232A1 (en) | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| MX2019001669A (es) | 2016-08-11 | 2019-09-27 | Ovid Therapeutics Inc | Metodos y composiciones para el tratamiento de trastornos epilepticos. |
| KR20200047557A (ko) | 2017-08-04 | 2020-05-07 | 오비드 테라퓨틱스 인크. | 당뇨병 및 관련 질환들의 치료에서 가복사돌의 사용 |
-
2018
- 2018-08-02 KR KR1020207006304A patent/KR20200047557A/ko not_active Withdrawn
- 2018-08-02 AU AU2018309049A patent/AU2018309049A1/en not_active Abandoned
- 2018-08-02 JP JP2020505905A patent/JP2020529440A/ja active Pending
- 2018-08-02 US US16/053,081 patent/US10813918B2/en not_active Expired - Fee Related
- 2018-08-02 CA CA3071939A patent/CA3071939A1/en active Pending
- 2018-08-02 WO PCT/US2018/044973 patent/WO2019028234A1/en not_active Ceased
- 2018-08-02 EP EP18840846.2A patent/EP3648762A4/en not_active Withdrawn
- 2018-08-02 MX MX2020001342A patent/MX2020001342A/es unknown
- 2018-08-02 CN CN201880065399.8A patent/CN111201022A/zh active Pending
-
2020
- 2020-02-02 IL IL272414A patent/IL272414A/en unknown
- 2020-10-08 US US17/066,389 patent/US11291658B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190038606A1 (en) | 2019-02-07 |
| IL272414A (en) | 2020-03-31 |
| WO2019028234A1 (en) | 2019-02-07 |
| EP3648762A1 (en) | 2020-05-13 |
| AU2018309049A1 (en) | 2020-02-27 |
| US11291658B2 (en) | 2022-04-05 |
| EP3648762A4 (en) | 2021-03-24 |
| CA3071939A1 (en) | 2019-02-07 |
| CN111201022A (zh) | 2020-05-26 |
| US20210030728A1 (en) | 2021-02-04 |
| US10813918B2 (en) | 2020-10-27 |
| KR20200047557A (ko) | 2020-05-07 |
| JP2020529440A (ja) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020001342A (es) | Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas. | |
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MY201603A (en) | Combination of dextromethorphan and bupropion for treating depression | |
| WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| JP2013505282A5 (OSRAM) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| RU2013148721A (ru) | Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения | |
| EA202191079A1 (ru) | Способы лечения синдрома ретта с применением фенфлурамина | |
| PH12013500808A1 (en) | Pharmaceutical combinations for the treatment of metabolic disorders | |
| BR112015001158A2 (pt) | formulação oftálmica e respectivo uso e método para melhorar, reduzir ou tratar presbiopia | |
| MY197558A (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
| FI3493812T3 (fi) | Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten | |
| RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
| EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
| JO3709B1 (ar) | تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز | |
| EP4316589A3 (en) | Treatment of patients with classic fabry disease | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| SG10201906172XA (en) | Regulation of glucose metabolism using anti-cgrp antibodies | |
| EA202090242A1 (ru) | Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов | |
| EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| WO2009005046A1 (ja) | ミゾリビンを含有する潰瘍性大腸炎治療薬 |